Creating and Sustaining Markets for Progress in Medicine

We believe that investment in innovation can and should enhance health system efficiency, while improving patient outcomes.

Strategy And Engagement Across The Business, Scientific, And Policy Domains

We have led joint efforts of industry, government, and civil society that evolved the practice of medicine development, evaluation, and use.

Business Domain
Scientific Domain
Policy Domain
The new normal in healthcare requires engagement across three domains

The new normal in healthcare:

  • Breakthroughs in science calling for new development, evaluation, and therapeutic use models
  • Increasing importance of data and analytics
  • Global demands for access regardless of economic means
  • Sharpening perspectives on value
  • Global challenges that no institution can address alone
Our Story

Flourishing in ‘the new normal’ requires the thoughtful integration of business strategy and external engagement across the full range of partners, to create and sustain markets for progress in medicine.

Galen/Atlantica specializes in: 

  • Creating new development, value recognition and access models to keep pace with evolving scientific and business realities, and overcome market failures 
  • Focusing external engagement to deliver patient benefit and commercial goals 
  • Convening and leading multi-party initiatives that serve the needs of all participants

Our Work

Innovation and Value Strategy

  • We developed new commercial models for antibiotics that reward innovation while safeguarding health system needs. These models are now being tested in national healthcare systems.

  • We developed a methodology for developers and reimbursement authorities to translate the efficacy of new medicines into outcomes through use of registries, real world evidence and risk shares.

  • We developed the integrated brand and medical plan for a billion-dollar development program for a previously untreatable condition.
Health Systems Analysis and Design

  • We developed the first-ever multi-country, multi-stakeholder early advice process focused on the value of a pipeline medicine and how to demonstrate it to regulators, HTAs, payers, clinicians and patients.We co-created the approach with the European Medicines Agency (EMA) and eight national health systems, and it has since been institutionalized by the EMA. Read More

  • We worked with a leading medical foundation to integrate the development and use of therapeutics and diagnostics in infectious disease. We led a multi-stakeholder collaboration using clinical scenarios as the basis for understanding and addressing drug-resistant infections. Read More
Responding to Emerging Science

  • We developed a policy strategy for a world leader in oncology to align the company’s external engagement with the cutting-edge science and commercial priorities for its largest therapeutic area.

  • We worked with the UK government to lead a 30-nation Summit of scientists and policymakers to prioritize 25 policy responses to antimicrobial resistance across human health and agriculture. The Summit outputs informed the 2016 UN High Level Meeting agenda on the topic.

  • We developed the policy and collaboration strategy to support the conditions for health systems to take up and use a disease-modifying treatment for Alzheimer’s disease.

Mobilizing Consortia for Action

  • We served in the core group that developed a pharmaceutical and diagnostics industry declaration setting out a balanced set of commitments and requirements for overcoming antimicrobial resistance.  The declaration was released at the World Economic Forum in Davos and has been subscribed to by 100 companies and 13 industry associations. Read More

  • We have co-lead multiple leadership networks of senior regulators, HTAs, payers, policymakers, KOLs and civil society to address the value of medicines, the sustainability of healthcare systems, and transition to reward for innovation on the basis of health outcomes.  

Leadership Team

FFMatt Diver and Nicholas Gertler founded Galen/Atlantica in Boston in 2015 after serving as partners at Tapestry Networks, where they led collaborations of senior executives of the pharmaceutical industry, government agencies, civil society and KOLs to advance responsive and sustainable healthcare innovation. 

Matt Diver

Matt’s career spans service as a Peace Corps Volunteer in Africa, as an investment banker focused on the technology sector, and a manager at BCG. He holds a business degree from UC Berkeley and a master’s in public policy from Harvard’s Kennedy School. 

Nicholas Gertler

Before his time at Tapestry, Nicholas was head of the CEO’s office of a $5B technology company, a McKinsey consultant, and an attorney in the Washington, DC office of Latham & Watkins. He holds masters’ in engineering and policy from the Massachusetts Institute of Technology and a JD from Harvard Law.

Case Study

Harnessing distributed expertise to tackle drug-resistant infections

In many clinical situations doctors need to treat patients with antibiotics without knowing what is causing their symptoms. This leads to widespread use of antibiotics where they are not needed, and the risk of using the wrong antibiotic where one is needed.   

The widespread adoption of faster and more accurate diagnostics would address this problem, but their development and introduction has been slow. Part of what’s missing has been a way to clearly define the different jobs to be done by diagnostics and the target performance characteristics they need to deliver. 

The workshop also identified four distinct diagnostic typologies in infectious disease, along with the different performance characteristics required from each category.  This much-needed specificity serves as a roadmap for clinicians, patients, technology developers, and policy-makers.  

To address this gap we:
  • Modeled the patient treatment pathway and potential roles for diagnostics for several bacterial infections. Pre-meeting briefing
  • Convened an interdisciplinary group of more than 50 leading experts (including diagnostics and drug developers, clinicians, patient representatives, regulators, HTAs and policymakers). 
  • Designed and led an interactive multi-day workshop using representative clinical scenarios to unlock the group’s collective knowledge
  • Worked with the Trust to synthesize and publish results 
  • Participants identified the fundamental importance of focusing not just on technologies but diagnostic strategies informed by (1) the specific clinical and health system context and (2) human factors such as physician behavior and patient attitudes. 

Contact us

We are based in Boston, Massachusetts, the biotech capital of the world.

Nicholas Gertler
+1 617-955-0996

Matt Diver
+1 617-852-9163